OncoKB New Data Release - September 29, 2025
Contact OncoKB
Data Release v5.2
September 29, 2025
What's New
We have updated the Level 1 annotation of ERBB2 Tyrosine Kinase Domain activating mutations in NSCLC (in association with zongertinib) to exclude the following mutations, which fall outside the TKD (ERBB2 V697L, Q709L, A710V and E717D)
Updated Therapeutic Implications:
Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
Level 2: Addition of Zongertinib to ERBB2 Oncogenic Mutations (excluding select Tyrosine Kinase Domain Activating Mutations, which are Level 1 in association with Zongertinib) in non-small cell lung cancer based on inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V8.2025 (PMID: 40293180)
Level 1 sensitivity-associated therapeutics currently in OncoKB™ for ERBB2 Oncogenic Mutations in non-small cell lung cancer: Trastuzumab Deruxtecan
Gene Curation:
Addition of 5 new genes:
We're Here to Help
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org
